Capricor Orphan Drug Designation for Becker Muscular Dystrophy, Regulatory Progress for Duchenne

 

• U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases
• Capricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscular Dystrophy following successful FDA Pre-License Inspection

https://finviz.com/news/82246/capricor-therapeutics-announces-orphan-drug-designation-for-becker-muscular-dystrophy-and-regulatory-progress-for-duchenne-muscular-dystrophy-program